Research ArticleTheranostics
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
Guillaume P. Nicolas, Seval Beykan, Hakim Bouterfa, Jens Kaufmann, Andreas Bauman, Michael Lassmann, Jean Claude Reubi, Jean E.F. Rivier, Helmut R. Maecke, Melpomeni Fani and Damian Wild
Journal of Nuclear Medicine June 2018, 59 (6) 909-914; DOI: https://doi.org/10.2967/jnumed.117.199737
Guillaume P. Nicolas
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
2Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
Seval Beykan
3Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
Hakim Bouterfa
4OctreoPharm Sciences GmbH, Ipsen Group, Berlin, Germany
Jens Kaufmann
4OctreoPharm Sciences GmbH, Ipsen Group, Berlin, Germany
Andreas Bauman
5Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland
Michael Lassmann
3Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
Jean Claude Reubi
6Cell Biology and Experimental Cancer Research, University of Berne, Berne, Switzerland
Jean E.F. Rivier
7Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California; and
Helmut R. Maecke
8Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
Melpomeni Fani
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
5Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland
Damian Wild
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
2Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 6
June 1, 2018
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
Guillaume P. Nicolas, Seval Beykan, Hakim Bouterfa, Jens Kaufmann, Andreas Bauman, Michael Lassmann, Jean Claude Reubi, Jean E.F. Rivier, Helmut R. Maecke, Melpomeni Fani, Damian Wild
Journal of Nuclear Medicine Jun 2018, 59 (6) 909-914; DOI: 10.2967/jnumed.117.199737
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
Guillaume P. Nicolas, Seval Beykan, Hakim Bouterfa, Jens Kaufmann, Andreas Bauman, Michael Lassmann, Jean Claude Reubi, Jean E.F. Rivier, Helmut R. Maecke, Melpomeni Fani, Damian Wild
Journal of Nuclear Medicine Jun 2018, 59 (6) 909-914; DOI: 10.2967/jnumed.117.199737
Jump to section
Related Articles
Cited By...
- 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
- Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
- Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists